Developer docs
API playgroundTry for free, no card

Search company profiles

ADCendo

Full company profile

uuid0000czf

Namestring
ADCendo
Legal namestring
Adcendo ApS
Websiteurl
adcendo.dk
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ADCendo (legal entity Adcendo ApS) is a Copenhagen-based, clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) engineered to address cancers with high unmet medical need. Its core technology combines monoclonal antibodies targeting novel cancer markers — including uPARAP/Endo180 and tissue factor — with cytotoxic payloads to deliver targeted therapy with reduced off-target effects relative to conventional chemotherapy. The company has three clinical-stage assets: ADCE-T02 (tissue factor-targeting, in cohort expansion of the Phase I Tiffany-01 study in advanced solid tumors and entering a Phase Ib combination with MSD's pembrolizumab in H2 2026), ADCE-D01 (FDA Orphan Drug Designation in soft tissue sarcoma, in Phase I), and ADCE-B05 (first patient dosed in Phase I for squamous cell tumors), supported by preclinical publications at AACR 2026 and in Molecular Cancer Therapeutics.

The company is pre-revenue and generates no product sales today. Its revenue model is structured around future licensing, royalty, and commercialization agreements with pharmaceutical partners, with go-to-market activity currently focused on advancing Phase I programs and securing strategic collaborations such as the MSD clinical trial supply agreement. ADCendo operates from Copenhagen, Denmark, with additional operations in Boston, Massachusetts, to support U.S. clinical development. The company is privately held and venture-backed, having raised approximately $325 million cumulatively across a 2021 Series A (Novo Seeds and Ysios Capital led), Series A extensions in 2023 and 2024 (the latter led by KKR-controlled Dawn Biopharma), a $135 million round in late 2024 (TCG Crossover led), and an oversubscribed $75 million Series C in April 2026 (Jeito Capital led). Investors include Novo Holdings, Ysios Capital, RA Capital Management, TPG, OrbiMed, Venrock, Gilde Healthcare, HealthCap, Pontifax, Surveyor Capital, Logos Capital, TCG Crossover, Jeito Capital, Vida Ventures, Bpifrance, EIFO, and Dawn Biopharma (KKR).

Short descriptiontext

ADCendo (Adcendo ApS) is a Copenhagen-based, clinical-stage biotech developing first- and best-in-class antibody-drug conjugates targeting uPARAP/Endo180 and tissue factor for cancers with high unmet need, currently advancing three Phase I programs (ADCE-T02, ADCE-D01, ADCE-B05).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFrederiksberg, Denmark
HQ citystring
Frederiksberg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, cancer therapeutics, oncology drug development, targeted cancer therapy, clinical-stage biotech
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Therapeutics — Antibody-Drug Conjugates (Biotech)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company developing ADC therapies for cancer treatment. Revenue will be generated through eventual drug commercialization, licensing deals, and partnerships upon successful clinical development.

adcendo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ADCendo is a clinical-stage biotech that discovers and develops antibody-drug conjugates (ADCs) — monoclonal antibodies linked to cytotoxic payloads — directed at novel cancer targets such as uPARAP/Endo180 and tissue factor. Its pipeline assets (ADCE-T02, ADCE-D01, ADCE-B05) target advanced solid tumors, soft tissue sarcoma, and squamous cell cancers, and the company monetizes through future licensing, partnerships, and commercialization. Revenue is not yet generated; the company funds development via venture capital and strategic pharma collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ADCE-T02 entered cohort expansion portion of Phase I Tiffany-01 study for advanced solid tumors
+3 more records
Product overview1 text field

Adcendo is a Copenhagen-based clinical-stage biotech company developing a pipeline of first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment. The company has three active clinical-stage ADC programs: ADCE-T02 (tissue factor-targeting, entering Phase Ib expansion with MSD collaboration), ADCE-D01 (FDA Orphan Drug Designation for soft tissue sarcoma), and ADCE-B05 (targeting squamous cell tumors). The lead pipeline asset targeting uPARAP/Endo180 was the foundation program. The company operates with headquarters in Copenhagen, Denmark and operations in Boston, Massachusetts.

Product and service4 records
1ADCE-T02
CategoryClinical-stage ADC (oncology therapeutic)
Description

A potentially best-in-class tissue factor-targeting antibody-drug conjugate (ADC) being evaluated in the Tiffany-01 Phase I study for advanced solid tumors; entered cohort expansion in 2026 and is also being studied in combination with pembrolizumab (KEYTRUDA) under an MSD collaboration.

2ADCE-D01
CategoryClinical-stage ADC (oncology therapeutic)
Description

Antibody-drug conjugate candidate targeting soft tissue sarcoma that received FDA Orphan Drug Designation and is advancing through Phase I clinical evaluation.

3ADCE-B05
CategoryClinical-stage ADC (oncology therapeutic)
Description

Antibody-drug conjugate targeting squamous cell tumors; first patient was dosed in its Phase I trial in 2026.

4uPARAP/Endo180 ADC Program
CategoryClinical-stage ADC (oncology therapeutic)
Description

Lead ADC program targeting uPARAP (also known as Endo180) for sarcoma and other cancer applications; the foundational pipeline asset around which the company was built.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Clinical trial collaboration and supply agreement to evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study for patients with advanced solid tumors. Adcendo sponsors the trial and MSD supplies pembrolizumab. Both companies retain commercial rights to their respective compounds. First patient dosing anticipated in H2 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) for cancer. Directly comparable as a clinical-stage ADC developer with multiple pipeline programs targeting solid tumors.

TypeDirect peer
Description

European clinical-stage biotech developing a pipeline of ADCs with proprietary linker and payload technologies. Comparable clinical-stage ADC company with similar technology positioning and European roots.

TypeDirect peer
Description

Clinical-stage ADC developer with multiple oncology programs in early-stage trials. Directly comparable as a clinical-stage company focused on ADC development for solid tumors.

TypeDirect peer
Description

Clinical-stage oncology company developing ADC and immuno-oncology therapeutics. Similar stage and business model with multiple ADC programs advancing through Phase I trials.

TypeDirect peer
Description

German clinical-stage biotech developing ADCs based on proprietary amanitin payload technology. Comparable clinical-stage ADC developer with proprietary platform approach and European HQ.

TypeEmerging player
Description

Clinical-stage biotech developing immune-stimulating antibody-drug conjugates (ISACs) for cancer. Comparable stage and oncology focus, though differentiated by immune-stimulating payload approach.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary linker and payload technology, advancing programs in solid tumors. Comparable clinical-stage ADC company with similar development-stage profile.

8Mythic Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing antibody-drug conjugates using a protein engineering approach for solid tumors. Comparable as an emerging ADC developer with early clinical assets.

TypeEmerging player
Description

Clinical-stage oncology biotech developing conditionally activated antibody therapeutics including probody-drug conjugates. Related oncology ADC-adjacent platform with established clinical pipeline.

TypeBroad incumbent
Description

Global pharmaceutical leader and ADC pioneer with Enhertu (DXd ADC platform). Industry incumbent in ADC development and commercialization, representing both the standard and the strategic partner/acquirer profile for clinical-stage ADC companies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ADCendo

Oncology Therapeutics — Antibody-Drug Conjugates (Biotech)adcendo.dk

ADCendo (Adcendo ApS) is a Copenhagen-based, clinical-stage biotech developing first- and best-in-class antibody-drug conjugates targeting uPARAP/Endo180 and tissue factor for cancers with high unmet need, currently advancing three Phase I programs (ADCE-T02, ADCE-D01, ADCE-B05).

What ADCendo does

ADCendo (legal entity Adcendo ApS) is a Copenhagen-based, clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) engineered to address cancers with high unmet medical need. Its core technology combines monoclonal antibodies targeting novel cancer markers — including uPARAP/Endo180 and tissue factor — with cytotoxic payloads to deliver targeted therapy with reduced off-target effects relative to conventional chemotherapy. The company has three clinical-stage assets: ADCE-T02 (tissue factor-targeting, in cohort expansion of the Phase I Tiffany-01 study in advanced solid tumors and entering a Phase Ib combination with MSD's pembrolizumab in H2 2026), ADCE-D01 (FDA Orphan Drug Designation in soft tissue sarcoma, in Phase I), and ADCE-B05 (first patient dosed in Phase I for squamous cell tumors), supported by preclinical publications at AACR 2026 and in Molecular Cancer Therapeutics.

The company is pre-revenue and generates no product sales today. Its revenue model is structured around future licensing, royalty, and commercialization agreements with pharmaceutical partners, with go-to-market activity currently focused on advancing Phase I programs and securing strategic collaborations such as the MSD clinical trial supply agreement. ADCendo operates from Copenhagen, Denmark, with additional operations in Boston, Massachusetts, to support U.S. clinical development. The company is privately held and venture-backed, having raised approximately $325 million cumulatively across a 2021 Series A (Novo Seeds and Ysios Capital led), Series A extensions in 2023 and 2024 (the latter led by KKR-controlled Dawn Biopharma), a $135 million round in late 2024 (TCG Crossover led), and an oversubscribed $75 million Series C in April 2026 (Jeito Capital led). Investors include Novo Holdings, Ysios Capital, RA Capital Management, TPG, OrbiMed, Venrock, Gilde Healthcare, HealthCap, Pontifax, Surveyor Capital, Logos Capital, TCG Crossover, Jeito Capital, Vida Ventures, Bpifrance, EIFO, and Dawn Biopharma (KKR).

ADCendo firmographics

Firmographics
Name
ADCendo
Legal name
Adcendo ApS
Website
https://adcendo.dk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
ADCendo (Adcendo ApS) is a Copenhagen-based, clinical-stage biotech developing first- and best-in-class antibody-drug conjugates targeting uPARAP/Endo180 and tissue factor for cancers with high unmet need, currently advancing three Phase I programs (ADCE-T02, ADCE-D01, ADCE-B05).
Ownership category
akta.pro rank

ADCendo industry classification

Industry
Product category
Oncology Therapeutics — Antibody-Drug Conjugates (Biotech)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Cancer therapeutics
  • Oncology drug development
  • Targeted cancer therapy
  • Clinical-stage biotech

Where ADCendo is headquartered

Location

Headquarters

HQ city
Frederiksberg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

ADCendo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing ADC therapies for cancer treatment. Revenue will be generated through eventual drug commercialization, licensing deals, and partnerships upon successful clinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

ADCendo product offering

Product offering

Core offering

ADCendo is a clinical-stage biotech that discovers and develops antibody-drug conjugates (ADCs) — monoclonal antibodies linked to cytotoxic payloads — directed at novel cancer targets such as uPARAP/Endo180 and tissue factor. Its pipeline assets (ADCE-T02, ADCE-D01, ADCE-B05) target advanced solid tumors, soft tissue sarcoma, and squamous cell cancers, and the company monetizes through future licensing, partnerships, and commercialization. Revenue is not yet generated; the company funds development via venture capital and strategic pharma collaborations.

Product overview

Adcendo is a Copenhagen-based clinical-stage biotech company developing a pipeline of first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment. The company has three active clinical-stage ADC programs: ADCE-T02 (tissue factor-targeting, entering Phase Ib expansion with MSD collaboration), ADCE-D01 (FDA Orphan Drug Designation for soft tissue sarcoma), and ADCE-B05 (targeting squamous cell tumors). The lead pipeline asset targeting uPARAP/Endo180 was the foundation program. The company operates with headquarters in Copenhagen, Denmark and operations in Boston, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADCE-T02 A potentially best-in-class tissue factor-targeting antibody-drug conjugate (ADC) being evaluated in the Tiffany-01 Phase I study for advanced solid tumors; entered cohort expansion in 2026 and is also being studied in combination with pembrolizumab (KEYTRUDA) under an MSD collaboration.
  • ADCE-D01 Antibody-drug conjugate candidate targeting soft tissue sarcoma that received FDA Orphan Drug Designation and is advancing through Phase I clinical evaluation.
  • ADCE-B05 Antibody-drug conjugate targeting squamous cell tumors; first patient was dosed in its Phase I trial in 2026.
  • uPARAP/Endo180 ADC Program Lead ADC program targeting uPARAP (also known as Endo180) for sarcoma and other cancer applications; the foundational pipeline asset around which the company was built.

Quantifiable outcome

  • ADCE-T02 entered cohort expansion portion of Phase I Tiffany-01 study for advanced solid tumors
  • +3 more outcomes

Companies that use ADCendo

Customer profile

Segments1 record

Ideal customer profiles2 records

ADCendo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ADCendo partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MSD (Merck & Co., Inc.)coreStrategic or Co-development Partner · 26 May 2026Clinical trial collaboration and supply agreement to evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study for patients with advanced solid tumors. Adcendo sponsors the trial and MSD supplies pembrolizumab. Both companies retain commercial rights to their respective compounds. First patient dosing anticipated in H2 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

ADCendo competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) for cancer. Directly comparable as a clinical-stage ADC developer with multiple pipeline programs targeting solid tumors.
  • Tubulis: European clinical-stage biotech developing a pipeline of ADCs with proprietary linker and payload technologies. Comparable clinical-stage ADC company with similar technology positioning and European roots.
  • ProfoundBio: Clinical-stage ADC developer with multiple oncology programs in early-stage trials. Directly comparable as a clinical-stage company focused on ADC development for solid tumors.
  • Pyxis Oncology: Clinical-stage oncology company developing ADC and immuno-oncology therapeutics. Similar stage and business model with multiple ADC programs advancing through Phase I trials.
  • Heidelberg Pharma: German clinical-stage biotech developing ADCs based on proprietary amanitin payload technology. Comparable clinical-stage ADC developer with proprietary platform approach and European HQ.
  • Byondis: Clinical-stage ADC developer with proprietary linker and payload technology, advancing programs in solid tumors. Comparable clinical-stage ADC company with similar development-stage profile.

Emerging players

  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody-drug conjugates (ISACs) for cancer. Comparable stage and oncology focus, though differentiated by immune-stimulating payload approach.
  • Mythic Therapeutics: Clinical-stage biotech developing antibody-drug conjugates using a protein engineering approach for solid tumors. Comparable as an emerging ADC developer with early clinical assets.
  • CytomX Therapeutics: Clinical-stage oncology biotech developing conditionally activated antibody therapeutics including probody-drug conjugates. Related oncology ADC-adjacent platform with established clinical pipeline.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical leader and ADC pioneer with Enhertu (DXd ADC platform). Industry incumbent in ADC development and commercialization, representing both the standard and the strategic partner/acquirer profile for clinical-stage ADC companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

ADCendo social profiles

Digital presence

ADCendo compliance and trust

Trust signal

Compliance1 record

ADCendo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ADCendo leadership team

Management profile

Number of profiles

Profiles7 records

ADCendo funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ADCendo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADCendo

What does ADCendo do?

ADCendo is a clinical-stage biotech that discovers and develops antibody-drug conjugates (ADCs) — monoclonal antibodies linked to cytotoxic payloads — directed at novel cancer targets such as uPARAP/Endo180 and tissue factor. Its pipeline assets (ADCE-T02, ADCE-D01, ADCE-B05) target advanced solid tumors, soft tissue sarcoma, and squamous cell cancers, and the company monetizes through future licensing, partnerships, and commercialization. Revenue is not yet generated; the company funds development via venture capital and strategic pharma collaborations.

Is ADCendo a public or private company?

ADCendo is a private company. It is classified as venture growth investor backed and is currently operating.

When was ADCendo founded?

ADCendo was founded in 2017. It employs 11 to 50 people.

Where is ADCendo based?

ADCendo is headquartered in Frederiksberg, Denmark, in the Europe region.

How does ADCendo make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are ADCendo's main competitors?

Direct peers on record are Mersana Therapeutics, Tubulis, ProfoundBio, Pyxis Oncology, Heidelberg Pharma and Byondis. Emerging players are Bolt Biotherapeutics, Mythic Therapeutics and CytomX Therapeutics. Daiichi Sankyo is listed as a broad incumbent.

Does ADCendo have an API?

No public API is recorded for ADCendo.

What industry is ADCendo in?

ADCendo's product category is Oncology Therapeutics — Antibody-Drug Conjugates (Biotech). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Trials ArenaMSD and Adcendo sign collaboration agreement for Phase Ib trialMSD and Adcendo signed a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda in a Phase Ib trial for advanced solid tumour patients. Adcendo will sponsor the trial, MSD will provide pembrolizumab, and both companies retain commercial rights. The first patient is expected to be dosed in the second half of 2026.PR NewswireAdcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid TumorsAdcendo ApS, a Copenhagen-based clinical-stage biotech company, has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.) to evaluate ADCE-T02, Adcendo's tissue factor-targeting antibody-drug conjugate, in combination with pembrolizumab (KEYTRUDA) in a Phase Ib study for patients with advanced solid tumors. Adcendo will sponsor the trial and anticipates dosing the first patient in the second half of 2026, while MSD will supply pembrolizumab; both companies retain commercial rights to their respective compounds.PR NewswireAdcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid TumorsAdcendo ApS, a Copenhagen-based clinical-stage biotech company focused on antibody-drug conjugates (ADCs) for cancer treatment, has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.) to evaluate ADCE-T02 in combination with KEYTRUDA® (pembrolizumab) in a Phase Ib study. Under the agreement, Adcendo will sponsor the Phase Ib study and MSD will supply pembrolizumab, with both companies retaining all commercial rights to their respective compounds. Adcendo anticipates dosing the first patient in the study in the second half of 2026.European BiotechnologyAdcendo inks MSD supply deal to run ADC-Keytruda combination studyAdcendo plans to start a Phase Ib trial in the second half of the year combining its TF-directed ADC ADCE-T02 with MSD's Keytruda. The trial aims to test safety and tolerability, potentially improving on Tivdak's adverse events. The company will test escalating doses of ADCE-T02 with the standard Keytruda dose.MedCity NewsWindward Bio Secures $165M for Clinical Trials in Asthma, COPD & MoreWindward Bio raised $165 million in a crossover round led by OrbiMed to advance its TSLP-blocking antibody WIN378. The drug is in Phase 2/3 testing with Phase 3 expected to start in Q4, and a COPD trial is planned this quarter. The funding extends its cash runway to reach multiple clinical trial readouts within 12 months.PR NewswireAdcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug ConjugatesAdcendo ApS announced multiple clinical and regulatory milestones for its pipeline of first- and best-in-class antibody-drug conjugates (ADCs), including ADCE-T02 advancing into the cohort expansion portion of the Tiffany-01 Phase I study in advanced solid tumors. The company also reported that ADCE-D01 received Orphan Drug Designation from the U.S. FDA for soft tissue sarcoma treatment, and the first patient was dosed in the Phase I trial of ADCE-B05 targeting squamous cell tumors. Preclinical data for ADCE-T02 was selected for poster presentation at the 2026 AACR Annual Meeting and published in Molecular Cancer Therapeutics, supporting the ADC's clinical development for tissue factor-positive cancers.PR NewswireAdcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug ConjugatesAdcendo ApS announced multiple clinical and regulatory milestones for its antibody-drug conjugate pipeline, including advancement of ADCE-T02 into cohort expansion in the Phase I Tiffany-01 study for advanced solid tumors and FDA Orphan Drug Designation for ADCE-D01 in soft tissue sarcoma. The company also reported that the first patient has been dosed in the Phase I trial of ADCE-B05, while preclinical data for ADCE-T02 was selected for poster presentation and publication at the AACR 2026 Annual Meeting. These developments advance Adcendo's three ADC programs targeting various solid tumors and sarcomas.NewswireAdcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug ConjugatesAdcendo announced updates on its ADC pipeline, including ADCE-T02 entering cohort expansion in the Tiffany-01 trial, ADCE-D01 receiving FDA Orphan Drug Designation for soft tissue sarcoma, and first patient dosing in the ADCE-B05 Phase I trial. The company plans to accelerate clinical programs with proceeds from its Series C financing.pharmaphorumBeeline raises $300m for BMS drugs, and other biofinancingsMultiple biopharma companies announced significant private financing rounds, with Beeline Medicines formally launching with a $300 million Series A funded by Bain Capital and a pipeline of immunology and inflammation drug candidates licensed from Bristol Myers Squibb. Oricell Therapeutics of Shanghai raised over $110 million in a pre-IPO round led by Vivo Capital and Qiming Venture Partners for its cell therapy pipeline targeting solid tumours and blood cancers, including Ori-C101 for liver cancer. Terremoto Biosciences secured $108 million Series C, Harbinger Health $100 million, Neomorph $100 million, Adcendo $75 million, and STORM Therapeutics $56 million to advance respective oncology and specialty drug development programmes.WebcapitalriesgoYsios Capital participa en la ronda Serie C de $75M de AdcendoYsios Capital participated in Adcendo's $75 million Series C round, led by Jeito Capital, with new investors including Vida Ventures, Bpifrance, and EIFO. The funding will support development of three ADC programs, including ADCE-T02, ADCE-D01, and ADCE-B05. Ysios Capital, which led the Series A in 2021, reaffirmed its confidence in the company.